Drugs & Targets FDA approves Fruzaqla for previously treated metastatic CRC November 10, 2023Vol.49 No.42
Clinical Roundup Taletrectinib shrinks tumors in NSCLC indication in phase II trial October 27, 2023Vol.49 No.40
Drugs & Targets FDA approves Tafinlar + Mekinist for pediatric patients with low-grade glioma with a BRAF V600E mutation March 17, 2023Vol.49 No.11
Drugs & Targets Gritstone bio and NCI collaborate to evaluate neoantigen cell therapy + vaccine for mutant KRAS solid tumors February 17, 2023Vol.49 No.07
Clinical Roundup Immunotherapy + targeted therapy for CRC shows positive phase II results February 03, 2023Vol.49 No.05
Clinical Roundup Rezlidhia shows positive results for mIDH1 AML in phase I/II study February 03, 2023Vol.49 No.05
In Brief Pedro Torres-Ayuso receives $50,000 to study gene as target in squamous cell head and neck cancers January 27, 2023Vol.49 No.04
Drugs & Targets FDA approves Rezlidhia for R/R AML with a susceptible IDH1 mutation December 02, 2022Vol.48 No.43
In Brief KUMC receives grant to increase targeted treatments to rural cancer patients November 18, 2022Vol.48 No.42
Clinical Roundup Phase Ib study shows positive results for combination targeted therapy for R/R AML November 18, 2022Vol.48 No.42
